tetano
Editor, Senior Moderator
Front Vet Sci
. 2022 Mar 14;9:815978.
doi: 10.3389/fvets.2022.815978. eCollection 2022.
A Spike Protein-Based Subunit SARS-CoV-2 Vaccine for Pets: Safety, Immunogenicity, and Protective Efficacy in Juvenile Cats
Kairat Tabynov[SUP] 1 2 3 [/SUP], Madiana Orynbassar[SUP] 1 [/SUP], Leila Yelchibayeva[SUP] 1 [/SUP], Nurkeldi Turebekov[SUP] 4 [/SUP], Toktassyn Yerubayev[SUP] 4 [/SUP], Nurali Matikhan[SUP] 1 [/SUP], Tlektes Yespolov[SUP] 1 [/SUP], Nikolai Petrovsky[SUP] 5 6 [/SUP], Kaissar Tabynov[SUP] 1 2 3 [/SUP]
Affiliations
Abstract
Whereas, multiple vaccine types have been developed to curb the spread of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) among humans, there are very few vaccines being developed for animals including pets. To combat the threat of human-to-animal, animal-to-animal, and animal-to-human transmission and the generation of new virus variants, we developed a subunit SARS-CoV-2 vaccine which is based on the recombinant spike protein extracellular domain expressed in insect cells and then formulated with appropriate adjuvants. Sixteen 8-12-week-old outbred female and male kittens (n = 4 per group) were randomly assigned into four treatment groups: spike protein alone; spike plus ESSAI oil-in-water (O/W) 1849102 adjuvant; spike plus aluminum hydroxide adjuvant; and a PBS control. All animals were vaccinated intramuscularly twice, 2 weeks apart, with 5 μg of spike protein in a volume of 0.5 ml. On days 0 and 28, serum samples were collected to evaluate anti-spike IgG, antibody inhibition of spike binding to angiotensin-converting enzyme 2 (ACE-2), neutralizing antibodies against wild-type and delta variant viruses, and hematology studies. At day 28, all groups were challenged with SARS-CoV-2 wild-type virus 10[SUP]6[/SUP] TCID[SUB]50[/SUB] intranasally. On day 31, tissue samples (lung, heart, and nasal turbinates) were collected for viral RNA detection, and virus titration. After two immunizations, both vaccines induced high titers of serum anti-spike IgG that inhibited spike ACE-2 binding and neutralized both wild-type and delta variant virus. Both adjuvanted vaccine formulations protected juvenile cats against virus shedding from the upper respiratory tract and viral replication in the lower respiratory tract and hearts. These promising data warrant ongoing evaluation of the vaccine's ability to protect cats against SARS-CoV-2 infection and in particular to prevent transmission.
Keywords: COVID-19; SARS-CoV-2; adjuvant; cats; delta variant; spike protein; vaccine.
. 2022 Mar 14;9:815978.
doi: 10.3389/fvets.2022.815978. eCollection 2022.
A Spike Protein-Based Subunit SARS-CoV-2 Vaccine for Pets: Safety, Immunogenicity, and Protective Efficacy in Juvenile Cats
Kairat Tabynov[SUP] 1 2 3 [/SUP], Madiana Orynbassar[SUP] 1 [/SUP], Leila Yelchibayeva[SUP] 1 [/SUP], Nurkeldi Turebekov[SUP] 4 [/SUP], Toktassyn Yerubayev[SUP] 4 [/SUP], Nurali Matikhan[SUP] 1 [/SUP], Tlektes Yespolov[SUP] 1 [/SUP], Nikolai Petrovsky[SUP] 5 6 [/SUP], Kaissar Tabynov[SUP] 1 2 3 [/SUP]
Affiliations
- PMID: 35372556
- PMCID: PMC8967242
- DOI: 10.3389/fvets.2022.815978
Abstract
Whereas, multiple vaccine types have been developed to curb the spread of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) among humans, there are very few vaccines being developed for animals including pets. To combat the threat of human-to-animal, animal-to-animal, and animal-to-human transmission and the generation of new virus variants, we developed a subunit SARS-CoV-2 vaccine which is based on the recombinant spike protein extracellular domain expressed in insect cells and then formulated with appropriate adjuvants. Sixteen 8-12-week-old outbred female and male kittens (n = 4 per group) were randomly assigned into four treatment groups: spike protein alone; spike plus ESSAI oil-in-water (O/W) 1849102 adjuvant; spike plus aluminum hydroxide adjuvant; and a PBS control. All animals were vaccinated intramuscularly twice, 2 weeks apart, with 5 μg of spike protein in a volume of 0.5 ml. On days 0 and 28, serum samples were collected to evaluate anti-spike IgG, antibody inhibition of spike binding to angiotensin-converting enzyme 2 (ACE-2), neutralizing antibodies against wild-type and delta variant viruses, and hematology studies. At day 28, all groups were challenged with SARS-CoV-2 wild-type virus 10[SUP]6[/SUP] TCID[SUB]50[/SUB] intranasally. On day 31, tissue samples (lung, heart, and nasal turbinates) were collected for viral RNA detection, and virus titration. After two immunizations, both vaccines induced high titers of serum anti-spike IgG that inhibited spike ACE-2 binding and neutralized both wild-type and delta variant virus. Both adjuvanted vaccine formulations protected juvenile cats against virus shedding from the upper respiratory tract and viral replication in the lower respiratory tract and hearts. These promising data warrant ongoing evaluation of the vaccine's ability to protect cats against SARS-CoV-2 infection and in particular to prevent transmission.
Keywords: COVID-19; SARS-CoV-2; adjuvant; cats; delta variant; spike protein; vaccine.
